BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37041591)

  • 1. Development of an antibody-ligand fusion protein scFvCD16A
    Li Y; Xie S; Chen M; Li H; Wang Y; Fan Y; An K; Wu Y; Xiao W
    Microb Cell Fact; 2023 Apr; 22(1):67. PubMed ID: 37041591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.
    Dowell AC; Oldham KA; Bhatt RI; Lee SP; Searle PF
    Cancer Immunol Immunother; 2012 May; 61(5):615-28. PubMed ID: 22021067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
    Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
    Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.
    Kermer V; Hornig N; Harder M; Bondarieva A; Kontermann RE; Müller D
    Mol Cancer Ther; 2014 Jan; 13(1):112-21. PubMed ID: 24198185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
    Müller D; Frey K; Kontermann RE
    J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
    Zhu H; Blum RH; Bjordahl R; Gaidarova S; Rogers P; Lee TT; Abujarour R; Bonello GB; Wu J; Tsai PF; Miller JS; Walcheck B; Valamehr B; Kaufman DS
    Blood; 2020 Feb; 135(6):399-410. PubMed ID: 31856277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo.
    Zhao XY; Jiang Q; Jiang H; Hu LJ; Zhao T; Yu XX; Huang XJ
    Eur J Immunol; 2020 Sep; 50(9):1374-1385. PubMed ID: 32357256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4
    Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H
    Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15.
    McArdel SL; Dugast AS; Hoover ME; Bollampalli A; Hong E; Castano Z; Leonard SC; Pawar S; Mellen J; Muriuki K; McLaughlin DC; Bayhi N; Carpenter CL; Turka LA; Wickham TJ; Elloul S
    Cancer Immunol Immunother; 2021 Sep; 70(9):2701-2719. PubMed ID: 34244816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.
    Battin C; De Sousa Linhares A; Leitner J; Grossmann A; Lupinek D; Izadi S; Castilho A; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Stritzker J; Steinberger P
    Cancer Immunol Immunother; 2023 Sep; 72(9):3029-3043. PubMed ID: 37310433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21.
    Li X; He C; Liu C; Ma J; Ma P; Cui H; Tao H; Gao B
    Int J Oncol; 2015 Jul; 47(1):335-42. PubMed ID: 25975533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model.
    Martinet O; Ermekova V; Qiao JQ; Sauter B; Mandeli J; Chen L; Chen SH
    J Natl Cancer Inst; 2000 Jun; 92(11):931-6. PubMed ID: 10841829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.
    Buechele C; Baessler T; Schmiedel BJ; Schumacher CE; Grosse-Hovest L; Rittig K; Salih HR
    Eur J Immunol; 2012 Mar; 42(3):737-48. PubMed ID: 22144129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity.
    Rabu C; Quéméner A; Jacques Y; Echasserieau K; Vusio P; Lang F
    J Biol Chem; 2005 Dec; 280(50):41472-81. PubMed ID: 16204238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo.
    Gong W; Xiao W; Qian L; Gong C; Hu M; Pan X; Ji M
    Cell Mol Immunol; 2010 Nov; 7(6):477-84. PubMed ID: 20871627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15.
    Gong W; Xiao W; Hu M; Weng X; Qian L; Pan X; Ji M
    Tissue Antigens; 2010 Dec; 76(6):467-75. PubMed ID: 20670353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy.
    Beha N; Harder M; Ring S; Kontermann RE; Müller D
    Mol Cancer Ther; 2019 Jul; 18(7):1278-1288. PubMed ID: 31040163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancer.
    Gulen AE; Rudraboina R; Tarique M; Ulker V; Shirwan H; Yolcu ES
    Cancer Immunol Immunother; 2023 Nov; 72(11):3567-3579. PubMed ID: 37605009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.